Abbonarsi

Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita - 09/02/13

Doi : 10.1016/j.jaad.2011.12.032 
Lars Komorowski, PhD a, Ralf Müller, PhD b, Artem Vorobyev, MD b, Christian Probst, PhD a, Andreas Recke, MD b, Marcel F. Jonkman, MD, PhD c, Takashi Hashimoto, MD d, Soo-Chan Kim, MD e, Richard Groves, MD, FRCP f, Ralf J. Ludwig, MD b, Detlef Zillikens, MD b, Winfried Stöcker, MD a, Enno Schmidt, MD, PhD b, g,
a Institute of Experimental Immunology, EUROIMMUN AG, Luebeck, Germany 
b Department of Dermatology, University of Luebeck, Luebeck, Germany 
g Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany 
c Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands 
d Department of Dermatology, Kurume University School of Medicine and Kurume University Institute of Cutaneous Cell Biology, Kurume, Japan 
e Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea 
f Department of Immunodermatology, St John’s Institute of Dermatology, St Thomas’ Hospital, London, United Kingdom 

Correspondence to: Enno Schmidt, MD, PhD, Department of Dermatology, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany.

Abstract

Background

Epidermolysis bullosa acquisita (EBA) is a severe autoimmune subepidermal blistering disease characterized by autoantibodies against the N-terminal collagenous domain (NC1) of type VII collagen (Col VII).

Objective

Development of reliable assays for the detection of anti-Col VII-NC1 antibodies.

Methods

NC1 was expressed in human HEK293 cells and used as target antigen in an enzyme-linked immunosorbent assay (ELISA) and in an immunofluorescence assay (IFA). These two assays were probed in a large cohort of patients with EBA (n = 73), bullous pemphigoid (BP, n = 72), anti-p200 pemphigoid (n = 24), anti-laminin 332 mucous membrane pemphigoid (MMP, n = 15), pemphigus vulgaris (PV, n = 24), and healthy control subjects (n = 254).

Results

The cut-off for the ELISA was optimized for accuracy by receiver-operating characteristics (area under the curve [AUC] = 0.9952). IgG reactivity against NC1 was detected in 69 of 73 EBA (94.5%) and 5 control sera (2 healthy controls and 3 BP patients), resulting in a specificity of 98.7%. The IFA showed a sensitivity of 91.8% and specificity of 99.8%. Reproducibility of the ELISA was demonstrated by an intra-class correlation coefficient of 0.97. IgG subclass analyses by ELISA revealed IgG1, IgG2, IgG3, and IgG4 anti-NC1 reactivity in 83.6%, 85.3%, 37.7%, and 83.6% of EBA sera, respectively.

Limitations

The novel assays were not evaluated prospectively and their use in monitoring serum levels during the disease course was not tested.

Conclusion

The two assays are highly specific and sensitive to diagnose EBA. Their diagnostic competence was demonstrated in a large cohort of well-characterized EBA sera.

Il testo completo di questo articolo è disponibile in PDF.

Key words : autoantibody, ELISA, immunofluorescence, type VII collagen

Abbreviations used : BP, Col VII, DEJ, EBA, ELISA, IF, NC1, PBS


Mappa


 Drs Komorowski and Müller contributed equally and are listed in alphabetical order.
 Funding sources: This work was supported by the Schleswig-Holstein Cluster of Excellence in Inflammation Research (DFG EXC 306/1) to E.S., D.Z., and R.L and the Graduiertenkolleg “Modulation of Autoimmunity” (GRK 1727/1) to A.V.
 Disclosure: Drs Probst and Stõcker are employees and shareholders of EUROIMMUN AG. Dr Komorowski is an employee of EUROIMMUN AG.


© 2012  American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 68 - N° 3

P. e89-e95 - marzo 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • Assessing students’ ability to detect melanomas using standardized patients and moulage
  • Claudia Hernandez, Robin Mermelstein, June K. Robinson, Rachel Yudkowsky
| Articolo seguente Articolo seguente
  • Acneiform eruptions associated with vemurafenib
  • Tatyana A. Petukhova, Roberto A. Novoa, Kord Honda, Henry B. Koon, Meg R. Gerstenblith

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.